Medpace Holdings, Inc. (NASDAQ:MEDP – Get Free Report) CEO August Troendle sold 3,510 shares of the company’s stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $600.01, for a total value of $2,106,035.10. Following the completion of the transaction, the chief executive officer owned 638,946 shares of the company’s stock, valued at $383,373,989.46. The trade was a 0.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.
Medpace Price Performance
Shares of MEDP stock opened at $577.11 on Friday. Medpace Holdings, Inc. has a one year low of $373.00 and a one year high of $677.90. The stock has a fifty day moving average price of $507.61 and a 200 day moving average price of $493.77. The stock has a market cap of $16.11 billion, a P/E ratio of 33.83, a price-to-earnings-growth ratio of 2.58 and a beta of 1.15.
Medpace (NASDAQ:MEDP – Get Free Report) last announced its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The firm had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. During the same quarter in the previous year, the firm posted $3.10 EPS. The business’s revenue for the quarter was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Equities research analysts anticipate that Medpace Holdings, Inc. will post 17.54 EPS for the current year.
Wall Street Analyst Weigh In
Read Our Latest Analysis on Medpace
Institutional Trading of Medpace
Several hedge funds have recently modified their holdings of the company. Geneos Wealth Management Inc. raised its stake in shares of Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after acquiring an additional 37 shares during the last quarter. Steigerwald Gordon & Koch Inc. bought a new stake in Medpace during the 4th quarter worth approximately $30,000. Elyxium Wealth LLC acquired a new stake in Medpace during the 4th quarter valued at $30,000. Allied Private Wealth LLC acquired a new position in Medpace in the second quarter worth $31,000. Finally, Basecamp Wealth Advisors LLC boosted its stake in Medpace by 187.5% in the first quarter. Basecamp Wealth Advisors LLC now owns 69 shares of the company’s stock worth $33,000 after purchasing an additional 45 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.
About Medpace
Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.
Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.
Featured Stories
- Five stocks we like better than Medpace
- Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector
- Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case
- Apple’s Record Quarter Could Not Outrun Its Guidance Problem
- McKesson’s Compounding Keeps Adding Up
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.
